---
title: "SL PHARM: Downgraded performance expectations，预计 losses of 73 million to 95 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233276826.md"
description: "SL PHARM released a revised performance forecast announcement for 2024, expecting a loss of 73 million to 95 million yuan for 2024, compared to the previous expectation of a loss of 32 million to 52 million yuan for 2024. The reason for the performance revision: As the company deepens the preparation work for the 2024 annual report and further collects and consolidates data from various subsidiaries, it was found that the previous performance forecast did not sufficiently offset certain items between the parent and subsidiary companies, resulting in discrepancies between the earlier forecast data and the actual situation"
datetime: "2025-03-26T11:37:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233276826.md)
  - [en](https://longbridge.com/en/news/233276826.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233276826.md)
generator: "portal-rs"
---

# SL PHARM: Downgraded performance expectations，预计 losses of 73 million to 95 million yuan in 2024

SL PHARM released a revised performance forecast announcement for the year 2024, expecting a loss of 73 million to 95 million yuan, compared to the previous estimate of a loss of 32 million to 52 million yuan for 2024. The reason for the performance revision: As the preparation work for the company's 2024 annual report deepens and the further collection and consolidation of data from various subsidiaries progresses, it was found that the offsetting of certain items between the parent and subsidiary companies in the performance forecast was insufficient, resulting in discrepancies between the previous performance forecast data and the actual situation

### Related Stocks

- [002038.CN](https://longbridge.com/en/quote/002038.CN.md)

## Related News & Research

- [Sopharma management commentary says H1 2026 earnings rise on higher sales, boosted by brands acquired in late 2024](https://longbridge.com/en/news/297315121.md)
- [BRAIN Biotech cuts FY 2025/26 BRAINBiocatalysts outlook, sees revenue growth below FY 2024/25 level](https://longbridge.com/en/news/297129636.md)
- [CVM orders Centaurus to launch Oncoclinicas tender offer by Oct. 24, 2026](https://longbridge.com/en/news/297244093.md)
- [Solution International Nordics signs LOI to buy Swedish baby, children’s products brand for SEK 8 million](https://longbridge.com/en/news/297270785.md)
- [AusperBio raises $120m to progress hepatitis B therapies](https://longbridge.com/en/news/297479238.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**